<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
</head>
<body>
<br>
<div class="moz-cite-prefix">On 01.04.21 06:34, Alex Balashov wrote:<br>
</div>
<blockquote type="cite"
cite="mid:187f6d01-2902-b273-769b-05421f90c56e@evaristesys.com">For
immediate release:
<br>
<br>
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in
partnership with
<br>
Posner | Palner Pharmaceuticals, are pleased to announce the
eagerly
<br>
anticipated start of Phase III clinical trials of Kamailio DMQ
module
<br>
replication.
<br>
<br>
In this stage of the investigation of the promising replication
scheme, which
<br>
was developed in record time, DMQ will be tested in a rigourous,
double-blind,
<br>
controlled CI/CD process for large-scale efficacy and continually
monitored for
<br>
safety in shorter and longer terms.
<br>
<br>
The now-concluded second phase established basic safety and Phase
2b entailed a
<br>
dose-finding study for the optimal number of batched `dmq_usrloc`
contacts per
<br>
kilogram of cloud computing resource.
<br>
<br>
The main cohort of the main sequence of the Phase III trial will
enroll 380
<br>
randomly selected, statistically representative Floridian SIP
registrars and
<br>
5700 SIP dialogs, also in the state of Florida. When asked about
the disparity
<br>
in the number of registrars versus dialogs, Alex Balashov of
Evariste said, "It
<br>
is reflective of the small number of SIP registrars in Florida;
not to be
<br>
indelicate, but consider the median age of the population."
<br>
<br>
As previously remarked upon in proceedings of the World SIP
Organisation (WSO),
<br>
the choice of Florida as a venue attracted some questions. We
asked Fred Posner
<br>
of Posner | Palner about the clinical background informing this
choice of
<br>
replication study cohort:
<br>
<br>
"Florida is a good place to find eventual consistency failures;
the open
<br>
climate and reluctance to accept traditional data integrity
science would have
<br>
sealed the deal, but when people started to drink bleach here, I
saw an
<br>
opportunity."
<br>
<br>
Evariste and Posner | Palner are aiming for a US Food & Drug
Administration EUA
<br>
(Emergency Use Authorisation) for DMQ replication as a
prophylactic data
<br>
redundancy and failover measure to ward off the development of
moderate to
<br>
severe viral Sonus Haemorrhagic Fever symptoms.
<br>
<br>
Phase II studies have painted a promising a picture of the DMQ
architecture's
<br>
ability to reduce moderate to severe symptoms and associated
28-day mortality
<br>
by more than 90%, albeit over a small sample size and in
enterprise patients
<br>
with known pre-existing comorbidities such as Session Border
Controller and
<br>
BroadSoft Multi-System Inflammatory Syndrome. Phase III trials
seek to bolster
<br>
quantums of broader efficacy, including efficacy for localised
outbreaks of
<br>
small to medium business softswitch.
<br>
<br>
Of the control group, Balashov said, "They will receive a standard
<br>
pipe-to-/dev/null placebo protocol, but with identical '200 OK'
confirmation
<br>
messages. We proudly developed this approach in early 2020 in
consultation with
<br>
the highest levels of the Trump presidential administration; it is
called
<br>
TENP, or 'The Emperor's New Potion.' It is a successor to that
administration's
<br>
previous approved placebo protocol, SHTI - Small Hands, Tremendous
Initiatives."
<br>
<br>
Despite speculative autism and packet fragmentation claims by
Florida Governor
<br>
Ron DeSantis, Balashov was quick to provide reassurance about side
effects from
<br>
DMQ in the Phase III trial.
<br>
<br>
"The incidence of severe allergies to plain-text UDP was within
standard
<br>
deviation over the mean for all insecure replication, and there's
support for
<br>
other transports on the way. Anyway, we have a robust adverse
effects reporting
<br>
system in our issue tracker and solid surveillance. Don't let
partisan politics
<br>
dissuade you from allowing request lines with the KDMQ method."
<br>
<br>
Other industry sources have reported that DMQ is not the only
replication
<br>
investigation undertaken by Evariste and Posner | Palner, although
it is the only
<br>
prophylactic suitable for the early infection development and
inflammatory
<br>
phases of a broad class of SBC-complex syndromes typically
afflicting service
<br>
providers. A recent IETF preprint by the same authors has shown
high-quality
<br>
preliminary data suggesting statistically significant improvement
in morbidity
<br>
outcomes from Perimeta and Nokia via a later-stage therapeutic
intervention
<br>
with a monoclonal, monorepo Github cocktail administered
intravenously.
<br>
<br>
<br>
</blockquote>
<br>
<p>Is it based on the bleeding-edge-proxy mSNA technology?</p>
<p>Does it do the microchip implant to the VoIP administrators or to
the subscribers?<br>
</p>
<p><i>Glossary</i><br>
</p>
<p> * mSNA: messenger SipoNucleic Action <br>
</p>
<p>Cheers,<br>
Daniel</p>
<pre class="moz-signature" cols="72">--
Daniel-Constantin Mierla -- <a class="moz-txt-link-abbreviated" href="http://www.asipto.com">www.asipto.com</a>
<a class="moz-txt-link-abbreviated" href="http://www.twitter.com/miconda">www.twitter.com/miconda</a> -- <a class="moz-txt-link-abbreviated" href="http://www.linkedin.com/in/miconda">www.linkedin.com/in/miconda</a>
Funding: <a class="moz-txt-link-freetext" href="https://www.paypal.me/dcmierla">https://www.paypal.me/dcmierla</a></pre>
</body>
</html>